S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$9.28
-0.72 (-7.20%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.81
$10.00
50-Day Range
$4.72
$10.00
52-Week Range
$1.05
$10.02
Volume
957,772 shs
Average Volume
919,999 shs
Market Capitalization
$573.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.71

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
15.5% Upside
$10.71 Price Target
Short Interest
Bearish
7.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Avadel Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$39,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.99) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

703rd out of 1,034 stocks

Pharmaceutical Preparations Industry

340th out of 502 stocks

AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Needham Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
What 5 Analyst Ratings Have To Say About Avadel Pharmaceuticals
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings
11/08/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$10.71
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+15.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-77,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.33 million
Book Value
($0.20) per share

Miscellaneous

Free Float
59,802,000
Market Cap
$573.32 million
Optionable
Optionable
Beta
1.62

Social Links


Key Executives

  • Mr. Gregory J. Divis Jr. (Age 55)
    CEO & Director
    Comp: $862.59k
  • Mr. Thomas S. McHugh (Age 57)
    Sr. VP & CFO
    Comp: $550k
  • Mr. Richard Kim (Age 53)
    Chief Commercial Officer
    Comp: $596.3k
  • Mr. Jerad G. Seurer
    Gen. Counsel & Company Sec.
  • Mr. Gregory J. Davis (Age 57)
    VP of Corp. and Bus. Devel.
  • Mr. Mark W. Elrod
    VP of Sales
  • Ms. Angie Woods
    VP of People & Culture
  • Mr. Christian Kalita Pharm.D
    Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan (Age 57)
    VP of Sales & Marketing and Head of Commercial Operations
  • Dr. Jordan S. Dubow M.D. (Age 44)
    Consultant













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month target prices for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they predict the company's stock price to reach $10.71 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2022?

Avadel Pharmaceuticals' stock was trading at $8.08 at the beginning of 2022. Since then, AVDL stock has increased by 14.9% and is now trading at $9.28.
View the best growth stocks for 2022 here
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.38). During the same quarter in the prior year, the company posted ($0.20) earnings per share.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Gendell Jeffrey L (8.00%), Brandes Investment Partners LP (4.52%), Renaissance Technologies LLC (1.32%), Citadel Advisors LLC (0.00%), Modera Wealth Management LLC (0.91%) and Two Sigma Investments LP (0.38%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends
.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $9.28.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $573.32 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 12/4/2022 by MarketBeat.com Staff